| Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells AI Rosenbaum, G Zhang, JD Warren, FR Maxfield Proceedings of the National Academy of Sciences 107 (12), 5477-5482, 2010 | 302 | 2010 |
| Nieman Pick C Disease: Molecular Mechanisms and Potential Therapeutic Approaches AI Rosenbaum, FR Maxfield, C Niemann-Pick Type J. Neurochem 116, 789-795, 2011 | 285 | 2011 |
| The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans YM Loo, PM McTamney, RH Arends, ME Abram, AA Aksyuk, S Diallo, ... Science translational medicine 14 (635), eabl8124, 2022 | 168 | 2022 |
| Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann− Pick type C disease therapeutics AI Rosenbaum, CC Cosner, CJ Mariani, FR Maxfield, O Wiest, P Helquist Journal of medicinal chemistry 53 (14), 5281-5289, 2010 | 101 | 2010 |
| Chemical screen to reduce sterol accumulation in Niemann–Pick C disease cells identifies novel lysosomal acid lipase inhibitors AI Rosenbaum, M Rujoi, AY Huang, H Du, GA Grabowski, FR Maxfield Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2009 | 65 | 2009 |
| First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody–drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer MD Pegram, EP Hamilton, AR Tan, AM Storniolo, K Balic, AI Rosenbaum, ... Molecular Cancer Therapeutics 20 (8), 1442-1453, 2021 | 50 | 2021 |
| Multiplex LC-MS/MS assays for clinical bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized … M Faria, M Peay, B Lam, E Ma, M Yuan, M Waldron, WR Mylott Jr, M Liang, ... Antibodies 8 (1), 11, 2019 | 43 | 2019 |
| Investigation of N-Aryl-3-alkylidenepyrrolinones as Potential Niemann−Pick Type C Disease Therapeutics CC Cosner, JT Markiewicz, P Bourbon, CJ Mariani, O Wiest, M Rujoi, ... Journal of medicinal chemistry 52 (20), 6494-6498, 2009 | 36 | 2009 |
| AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans YM Loo, PM McTamney, RH Arends, RA Gasser Jr, ME Abram, A Aksyuk, ... Medrxiv, 2021.08. 30.21262666, 2021 | 35 | 2021 |
| 2018 White Paper on Recent Issues in Bioanalysis: ‘A global bioanalytical community perspective on last decade of incurred samples reanalysis (ISR)’ (Part 1 … J Welink, Y Xu, E Yang, A Wilson, N Henderson, L Luo, S Fraser, U Kavita, ... Bioanalysis 10 (22), 1781-1801, 2018 | 34 | 2018 |
| Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease S Pechenov, J Revell, S Will, J Naylor, P Tyagi, C Patel, L Liang, L Tseng, ... Scientific reports 11 (1), 22521, 2021 | 33 | 2021 |
| Recent developments in the synthesis of 1, 2, 5-thiadiazoles and 2, 1, 3-benzothiadiazoles OA Rakitin Synthesis 51 (23), 4338-4347, 2019 | 30 | 2019 |
| ADME considerations and bioanalytical strategies for pharmacokinetic assessments of antibody-drug conjugates S Mou, Y Huang, AI Rosenbaum Antibodies 7 (4), 41, 2018 | 30 | 2018 |
| Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody–drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide JS de Bono, MT Fleming, JS Wang, R Cathomas, MS Miralles, J Bothos, ... Clinical Cancer Research 27 (13), 3602-3609, 2021 | 22 | 2021 |
| Characterization of Antibody–Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM Y Huang, S Mou, Y Wang, R Mu, M Liang, AI Rosenbaum Analytical Chemistry 93 (15), 6135-6144, 2021 | 21 | 2021 |
| AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans (preprint) YM Loo, PM McTamney, RH Arends, RA Gasser Jr, ME Abram, A Aksyuk, ... | 20 | 2021 |
| Design and preclinical evaluation of a novel B7-H4–directed antibody–drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305 K Kinneer, P Wortmann, ZA Cooper, NJ Dickinson, L Masterson, ... Clinical Cancer Research 29 (6), 1086-1101, 2023 | 17 | 2023 |
| Targeted oral peptide delivery using multi-unit particulates: Drug and permeation enhancer layering approach P Tyagi, R Trivedi, S Pechenov, C Patel, J Revell, S Wills, Y Huang, ... Journal of Controlled Release 338, 784-791, 2021 | 17 | 2021 |
| Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial JE Le Lay, Q Du, MB Mehta, N Bhagroo, BT Hummer, J Falloon, ... Science Translational Medicine 13 (590), eabb0602, 2021 | 17 | 2021 |
| 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1 … S Kaur, SC Alley, M Szapacs, A Wilson, E Ciccimaro, D Su, N Henderson, ... Bioanalysis 14 (9), 505-580, 2022 | 16 | 2022 |
Yue HuangRevolution MedicinesVerified email at revmed.com
